I will not go into detail for each stock, but there are three in this list that should be noted. Caracal, Heritage Oil and Smith & Nephew have all been the target of bid approaches. A similar situation was seen with AstraZeneca last month. These shares have been rapidly pushed higher, but if the bid fails to materialize, as happened with Astra, the shares can drop back. Thus I would look to exclude these from the strategy.